Alendronate reduces the excretion of risk factors for calcium phosphate stone formation in postmenopausal women with osteoporosis

Urologia Internationalis

Volumn 83, Issue 2, 2009, Pages 226-229

  Yasui, Takahiro ^a   Itoh, Yasunori ^a   Okada, Atsushi ^a   Hamamoto, Shuzo ^a   Hirose, Masahito ^a   Kobayashi, Takahiro ^a   Tozawa, Keiichi ^a   Kohri, Kenjiro ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

Alendronate; Bisphosphonate; Bone markers; Bone mineral density; Calcium phosphate; Calculus; Nephrolithiasis

Indexed keywords

ALENDRONIC ACID; BONARON; CALCIUM OXALATE; CALCIUM PHOSPHATE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BONE DENSITY; CALCIUM STONE; CALCIUM URINE LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; EXCRETION; FEMALE; HUMAN; MALE; OSTEOPOROSIS; PATHOGENESIS; POSTMENOPAUSE; PRIORITY JOURNAL; RISK FACTOR; STONE FORMATION;

ALENDRONATE; BONE DENSITY CONSERVATION AGENTS; CALCIUM PHOSPHATES; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS; POSTMENOPAUSE; RISK FACTORS; URINARY CALCULI;

EID: 70349288427     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000230029     Document Type: Article

References (23)

1. Siener R, Hesse A: Recent advances in nutritional research on urolithiasis. World J Urol 2005; 23: 304-308.
2. Yasui T, Iguchi M, Suzuki S, Kohri K: Prevalence and epidemiological characteristics of urolithiasis in Japan: National trends between 1965 and 2005. Urology 2008; 71: 209-213.
3. Stamatelou KK, Francis ME, Jones CA, Nyberg LM, Curhan GC: Time trends in reported prevalence of kidney stones in the United States: 1976-1994. Kidney Int 2003; 63: 1817-1823.
4. Hesse A, Brandle E, Wilbert D, Kohrmann KU, Alken P: Study on the prevalence and incidence of urolithiasis in Germany comparing the years 1979 vs. 2000. Eur Urol 2003; 44: 709-713.
5. Goldfarb DS: Increasing prevalence of kidney stones in the United States. Kidney Int 2003; 63: 1951-1952.
6. Caudarella R, Vescini F, Buffa A, La Manna G, Stefoni S: Osteoporosis and urolithiasis. Urol Int 2004; 72(supp 1):17-19.
7. Jaeger P, Lippuner K, Casez JP: Low bone mass in idiopathic renal stone formers: Magnitude and significance. J Bone Miner Res 1994; 9: 1525-1532. (Pubitemid 24300101)
8. Tugcu V, Ozbek E, Aras B, Ozbay B, Islim F, Tasci AI: Bone mineral density measurement in patients with recurrent normocalciuric calcium stone disease. Urol Res 2007; 35: 29-34.
9. Liberman UA, Weiss SR, Bröll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW, Dequeker J, Favus M: Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995; 333: 1437-1443.
10. Ebisuno S, Kohjimoto Y, Nishikawa T, Nishihata M, Inagaki T, Komura T, Ohkawa T: Effects of etidronate disodium on crystallizations in synthetic urine and calcium oxalate crystal adhesion to Madin-Darby Canine Kidney (MDCK) cells. Int J Urol 1998; 5: 582-587.
11. Bone HG, Zerwekh JE, Britton F, Pak CY: Treatment of calcium urolithiasis with diphosphonate: Efficacy and hazards. J Urol 1979; 121: 568-571.
12. Bevilacqua M, Dominguez LJ, Rosini S, Barbagallo M: Bisphosphonates and atherosclerosis: Why? Lupus 2005; 14: 773-779.
13. Senzaki H, Yasui T, Okada A, Ito Y, Tozawa K, Kohri K: Alendronate inhibits urinary calcium microlith formation in a three-dimensional culture model. Urol Res 2004; 32: 223-228.
14. Orimo H, Sugioka Y, Fukunaga M, Muto Y, Hotokebuchi T, Gorai I, Nakamura T, Kushida K, Tanaka H, Ikai T, Oh-hashi Y: Diagnostic criteria of primary osteoporosis. J Bone Miner Metab 1998; 16: 139-150.
15. Tiselius TG: Metabolic evaluation of patients with stone disease. Urol Int 1997; 59: 131-141.
16. Fleish H: Bisphosphonates - history and experimental basis. Bone 1987; 8(suppl 1):S23-S28.
17. Azuma Y, Chokki M, Ohta T, Kiyoki M: Effects of alendronate on plasma calcium levels, levels, urinary calcium excretion, and bone resorption markers in normal rats: Comparison with elcatonin, synthetic eel calcitonin. Endocrinology 1996; 137: 2586-2592.
18. Vaidyanathan S, Watson ID, Jonsson O, Buczynski AZ, Grases F, Heilberg IP, Yasui T, Tozawa K, Kohri K, Schurch B, Hughes PL, Singh G, Soni BM, Sett P, Fraser WD: Recurrent vesical calculi, hypercalciuria, and biochemical evidence of increased bone resorption in an adult male with paraplegia due to spinal cord injury: Is there a role for intermittent oral disodium etidronate therapy for prevention of calcium phosphate bladder stones? Spinal Cord 2005; 43: 269-277.
19. Cremers SC, Pillai G, Papapoulos SE: Pharmacokinetics/pharmacodynamics of bisphosphonates: Use for optimisation of intermittent therapy for osteoporosis. Clin Pharmacokinet 2005; 44: 551-570.
20. National Osteoporosis Foundation. Physician's Guide to Prevention and Treatment of Osteoporosis. Belle Mead, Excerpta Medica, 1999.
21. Khan SR, Thamilselvan S: Nephrolithiasis: A consequence of renal epithelial cell exposure to oxalate and calcium oxalate crystals. Mol Urol 2000; 4: 305-312.
22. Tiselius HG: Epidemiology and medical management of stone disease. BJU Int 2003; 91: 758-767.
23. Matlaga BR, Coe FL, Evan AP, Lingeman JE: The role of Randall's plaques in the pathogenesis of calcium stones. J Urol 2007; 177: 31-38.